AIDS · 1998 · 282 citations · 5 references
MedicineDermatologyEndocrinologyDermatopathologyDiabetologyMolecular PathologyDiabetes ManagementDiabetes MellitusInsulin ResistanceInsulin TherapyLipid Metabolism DisordersWeight LossImpaired Glucose ToleranceInsulin Resistance SyndromeSubcutaneous Fat DepositionSubcutaneous Fat Loss
BACKGROUND: Lipodystrophies are rare cutaneous disorders characterized by the symmetrical loss of subcutaneous fat from the body surface. The cause of lipodystrophy is not known, but a possible genetic predisposition is likely and either overt diabetes mellitus or insulin resistance are often associated. DESIGN AND METHODS: Case study. PATIENTS: Eight patients who developed either partial or generalized lipodystrophy after protease inhibitor therapy. RESULTS: In all eight patients lipodystrophy occurred after 2-12 months of starting indinavir and was not preceded by weight loss or inflammatory skin disease. Short-term follow-up after withdrawal of therapy showed no change in the patients' appearance. One patient developed glycosuria as lipodystrophy became manifest. In three cases glucose tolerance test was performed revealing a high level of insulin between the first and third hour of loading. CONCLUSIONS: In our view, lipodystrophy is an unwanted side-effect of protease inhibitor therapy causing noticeable disfigurement.
5
Marked hyperlipidaemia on ritonavir therapy.
Arlene Sullivan, Matthew R. Nelson · PubMed · 1997 · 110 citations
Partial lipodystrophy in coeliac disease.
Denis O’Mahony, Siobhain M. O’Mahony, M. J. Whelton et al. · Gut · 1990 · 20 citations · Full text
Medicine, Dermatology, Pathology +11
Lipodystrophy, pancreatitis, and eosinophilia.
P M Smith, M.E. Morgans, C G Clark et al. · Gut · 1975 · 19 citations · Full text